Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.57 |
| ▸ | KRAS | P01116 | 2/20 | 0.54 |
| ▸ | PNP | P00491 | 1/20 | 0.53 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.53 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.53 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | ENTPD1 | P49961 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1762981 | 1.00 | TGM2 (0.57) | TGM2KRASPNPFUT5P2RX3 | |
| SCHEMBL6041237 | 0.99 | TGM2 (0.57) | TGM2KRASPNPFUT5P2RX3 | |
| SCHEMBL6041235 | 0.99 | TGM2 (0.57) | TGM2KRASPNPFUT5P2RX3 | |
| SCHEMBL2775572 | 0.92 | PNP (0.58) | TGM2PNPNT5EALDH1A1MAPT | |
| SCHEMBL20277567 | 0.92 | PNP (0.58) | TGM2PNPNT5EALDH1A1MAPT | |
| SCHEMBL15522523 | 0.92 | PNP (0.58) | TGM2PNPNT5EALDH1A1MAPT | |
| SCHEMBL5315097 | 0.91 | TGM2 (0.58) | TGM2KRASPNPFUT5P2RX3 | |
| SCHEMBL5315091 | 0.91 | TGM2 (0.58) | TGM2KRASPNPFUT5P2RX3 | |
| SCHEMBL17893049 | 0.91 | PNP (0.66) | TGM2KRASPNPFUT5P2RX3 | |
| SCHEMBL15794376 | 0.89 | TGM2 (0.59) | TGM2KRASPNPFUT5P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614312-B2 | Method for preparing nucleotides and related analogues by synthesis on soluble substrate, and biological tools thus prepared | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-12-24 | — | — | US | disclosed |
| US-20130203726-A1 | FtsZ INHIBITORS AS POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS | ROEMER TERRY (US) | 2013-08-08 | — | — | US | disclosed |
| US-8383597-B2 | G proteins in tumor growth and angiogenesis | CORNELL RESEARCH FOUNDATION, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2544528-A1 | FtsZ INHIBITORS AS POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS | Merck Sharp & Dohme Corp. (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2011112435-A1 | FtsZ INHIBITORS AS POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS | MERCK SHARP & DOHME CORP. (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110118454-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-05-19 | — | — | US | disclosed |
| EP-2265624-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | Centre National de la Recherche Scientifique (FR) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009115694-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-09-24 | — | — | WO | disclosed |
| US-20080020994-A1 | G proteins in tumor growth and angiogenesis | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203726-A1 | FtsZ INHIBITORS AS POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS | RCE1, POLE3, MCRS1 | TGM2 1812/4885KRAS 748/4885PNP 2507/4885 |
| US-20110118454-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | PNP, NUDT1, DUT | TGM2 4427/4885KRAS 2282/4885PNP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.